2020
HMGB1 Is a Therapeutic Target and Biomarker in Diazepam-Refractory Status Epilepticus with Wide Time Window
Zhao J, Zheng Y, Liu K, Chen J, Lai N, Fei F, Shi J, Xu C, Wang S, Nishibori M, Wang Y, Chen Z. HMGB1 Is a Therapeutic Target and Biomarker in Diazepam-Refractory Status Epilepticus with Wide Time Window. Neurotherapeutics 2020, 17: 710-721. PMID: 31802434, PMCID: PMC7283397, DOI: 10.1007/s13311-019-00815-3.Peer-Reviewed Original ResearchConceptsHigh mobility group box 1Anti-HMGB1 mAbStatus epilepticusTherapeutic targetLife-threatening neurological emergencyToll-like receptor 4 (TLR4)-dependent pathwayAnti-HMGB1 monoclonal antibodyNeutralization of HMGB1Plasma HMGB1 levelsMobility group box 1Severity of seizure activityExogenous high mobility group box 1Incidence of SENonrefractory SEHMGB1 levelsPredictive biomarkersTherapeutic responseNeurological emergencyTherapeutic windowBox 1Seizure activityMonoclonal antibodiesPharmacological therapeuticsSE periodEpilepticus
2019
Multidisciplinary management improves anxiety, depression, medication adherence, and quality of life among patients with epilepsy in eastern China: A prospective study
Zheng Y, Ding X, Guo Y, Chen Q, Wang W, Zheng Y, Wang S, Ding Y, Ding M. Multidisciplinary management improves anxiety, depression, medication adherence, and quality of life among patients with epilepsy in eastern China: A prospective study. Epilepsy & Behavior 2019, 100: 106400. PMID: 31634729, DOI: 10.1016/j.yebeh.2019.07.001.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnticonvulsantsAnxietyChinaCombined Modality TherapyDepressionEpilepsyFemaleFollow-Up StudiesHumansInterdisciplinary CommunicationMaleMedication AdherenceMiddle AgedPatient Care TeamProspective StudiesPsychiatric Status Rating ScalesQuality of LifeSelf ReportSingle-Blind MethodTreatment OutcomeYoung AdultConceptsQuality of lifeMedication adherenceIntervention groupMultidisciplinary programBeck Anxiety InventoryBeck Depression InventoryEight-item Morisky Medication Adherence ScaleMorisky Medication Adherence ScaleEpilepsy specialist nursesOverall QOLIE-31 scoreSelf-reported seizure frequencyMedication Adherence ScaleQOLIE-31 scoresAntiepileptic drug adherenceSpecialist nursesMMAS-8Epilepsy-31Adherence ScaleSeverity of depressionQOLIE-31Anxiety InventoryTertiary hospitalDepression InventorySevere depressionPsychiatric comorbidities
2017
Active epilepsy prevalence, the treatment gap, and treatment gap risk profile in eastern China: A population-based study
Ding X, Zheng Y, Guo Y, Shen C, Wang S, Chen F, Yan S, Ding M. Active epilepsy prevalence, the treatment gap, and treatment gap risk profile in eastern China: A population-based study. Epilepsy & Behavior 2017, 78: 20-24. PMID: 29161630, DOI: 10.1016/j.yebeh.2017.10.020.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnticonvulsantsChildChild, PreschoolChinaCross-Sectional StudiesEpilepsyFemaleHealth Services AccessibilityHealthcare DisparitiesHumansInfantInfant, NewbornInsurance, HealthMaleMiddle AgedPrevalenceRisk FactorsSeizuresSocioeconomic FactorsSurveys and QuestionnairesYoung AdultConceptsPrevalence of active epilepsyTreatment gapActive epilepsyCross-sectional population-based surveyLack of health insuranceActive epilepsy prevalencePopulation-based surveyMulti-stage cluster samplingPopulation-based studyRisk profileSeizure frequencyHealth insurance systemLogistic regression analysisEpilepsy prevalenceHealth insuranceAnalyze risk factorsAssociated with higher seizure frequencyCluster samplingReducing seizure frequencyRisk factorsHigher seizure frequencyInsurance systemRegression analysisAntiepileptic treatmentPrevalence